retatrutide nonalcoholic steatohepatitis nash trial Oligonucleotide therapies for retatrutide nonalcoholic steatohepatitis nash trial

The temporal distribution of AE onset demonstrated a median time of 59 days (interquartile range: 16212 days), indicating substantial variability in the latency period of adverse events

This rise is fuelling a parallel increase in obesity-related diseases, including type 2 diabetes [3], cardiovascular disease [4], and, critically, cancer

Physical properties Spectral properties Usage and storage Contact us Page updated on July 12, 2023

Here, we review the current knowledge on the role of estrogens and estrogen-like molecules in the neuro/gliogenic processes and the regulation of neuronal survival and neurodegeneration

doi: 10.1038/s41467-023-42424-x 260